2024-01-31 15:19:39 ET
Summary
- Disc Medicine, Inc. has seen a strong rally in its stock after positive open-label data from its lead heme biosynthesis program, bitopertin.
- Results from a placebo-controlled trial, expected in early 2024, will validate bitopertin's efficacy and could lead to a registrational trial in late 2024 or early 2025.
- Disc Medicine has a cash runway until 2026, but its domestic peak-sales potential is somewhat limited.
- A full investment analysis around Disc Medicine follows in the paragraphs below.
The best blood will at some time get into a fool or a mosquito . - Austin O'Malley.
Read the full article on Seeking Alpha
For further details see:
Disc Medicine: What's Behind The Huge Rally